Daewoong pharmaceutical Co.,Ltd
069620.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
$158230.73
50.8% upside
Current Fair Value
50.8% upsideUndervalued by 50.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | - |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 18.37% |
|---|---|
| Return on Assets | 7.70% |
| Return on Invested Capital | 11.28% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | 0.87 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$422.13 B
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$445.49 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Daewoong pharmaceutical Co.,Ltd
1,794 employees
CEO: Chang-Jae Lee Established in 1945 and headquartered in Seoul, South Korea, Daewoong Pharmaceutical Co., Ltd. is a global entity dedicated to the research, production, and international distribution of a diverse range of pharmaceutical products. Its ex...